Biosimilar insulin is an attractive market to a number of American and European pharmaceutical companies. Biosimilar insulin manufacture is complicated for a number of reasons. Guest host Dr. Timothy Bailey talks with Dr. Lutz Heinemann, director of scientific services at Profil Institute for Clinical Research in San Diego and headquartered in Neuss, Germany, about the challenges and guidelines around producing safe and effective biosimilars. And, for healthcare providers, what are the practical aspects of switching to a biosimilar insulin?